,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['trastuzumab', 'breast']
a few hours before #ascoplenary we have the impressive findings of destiny breast- 04 published in #nejm. the #trastuzumabderuxtecan has activity in all spectrum of her-2. looking forward discussion in the plenary session. #asco22 
Interested in #Breastcancer #Cancerreseach.